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Abstract
Nipah virus (NiV) outbreaks have occurred in Malaysia, India, and Bangladesh, and the virus 
continues to cause annual outbreaks of fatal human encephalitis in Bangladesh due to spillover 
from its bat host reservoir. Due to its high pathogenicity, its potential use for bio/agro-terrorism, 
and to the current lack of approved therapeutics, NiV is designated as an overlap select agent 
requiring biosafety level-4 containment. Although the development of therapeutic monoclonal 
antibodies and soluble protein subunit vaccines have shown great promise, the paucity of effective 
antiviral drugs against NiV merits further exploration of compound libraries using rapid 
quantitative antiviral assays. As a proof-of-concept study, we evaluated the use of fluorescent and 
luminescent reporter NiVs for antiviral screening. We constructed and rescued NiVs expressing 
either Renilla luciferase or green fluorescent protein, and characterized their reporter signal 
kinetics in different cell types as well as in the presence of several inhibitors. The 50% effective 
concentrations (EC50s) derived for inhibitors against both reporter viruses are within range of 
EC50s derived from virus yield-based dose–response assays against wild-type NiV (within 
1Log10), thus demonstrating that both reporter NiVs can serve as robust antiviral screening tools. 
Utilizing these live NiV-based reporter assays requires modest instrumentation, and circumvents 
the time and labor-intensive steps associated with cytopathic effect or viral antigen-based assays. 
These reporter NiVs will not only facilitate antiviral screening, but also the study of host cell 
components that influence the virus life cycle.
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1. Introduction
Nipah virus (NiV) is a highly pathogenic paramyxovirus in the genus Henipavirus of the 
subfamily Paramyxovirinae within the family Paramyxoviridae (Rota and Lo, 2012). 
Humans are infected upon spillover of NiV from its bat reservoir host or by person-to-
person transmission (Luby, 2013). Due to its high pathogenicity, its potential use for bio/
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agro-terrorism, and to the current lack of approved therapeutics, NiV is designated as an 
overlap select agent requiring biosafety level-4 containment. Although several preventative 
measures against exposure to bat saliva or urine have been studied (Nahar et al., 2013), NiV 
continues to cause near-annual outbreaks of fatal encephalitis in Bangladesh. The 
development of therapeutic monoclonal antibodies and soluble subunit vaccines against 
henipaviruses have shown great promise (Broder et al., 2013), but screening available 
compound libraries for potentially efficacious therapeutics against NiV remains a high 
priority for investigation. Most high-throughput antiviral assays against NiV were developed 
to screen for inhibitors of virus entry and/or cell-to-cell fusion (Bossart et al., 2005; Porotto 
et al., 2009; Talekar et al., 2012; Tamin et al., 2009), while the NiV minigenome assay was 
used to screen for inhibitors of NiV replication (Freiberg et al., 2008). A chemiluminescent 
immunodetection assay for live henipavirus infection significantly streamlined antiviral 
screening when compared with cytopathic effect (CPE) or immune plaque-based assays, but 
had relatively limited signal-to-noise ratios (<100), and also required cell fixation and 
multiple incubation steps which are time and labor-intensive (Aljofan et al., 2008). Reverse 
genetic systems for henipaviruses have enabled the generation of recombinant viruses 
expressing fluorescent or luminescent proteins which allow for rapid detection of infection 
in vitro and in vivo (Lo et al., 2012; Marsh et al., 2013; Yoneda et al., 2006). We sought to 
determine whether NiVs expressing fluorescent or luminescent reporters could facilitate 
rapid quantitative antiviral screening. As a proof-of-concept study, we constructed and 
rescued NiVs expressing either Renilla luciferase (LUC2AM) or green fluorescent protein 
(GFP2AM), characterized their reporter signal kinetics in different human cell types, and 
tested them in parallel against cellular inhibitors of pyrimidine biosynthesis as well as innate 
immune agonists. We show that both reporter viruses can be used in the 96-well format and 
have excellent signal-to-noise ratios and Z′-factors. Furthermore, the 50% effective 
concentrations (EC50s) derived for inhibitors tested against both reporter viruses were not 
only within close range of one another (within 4-fold), but also of EC50s derived from virus 
yield-based dose–response assays against wild-type NiV (within 1 Log10), thus 
demonstrating that both reporter NiVs can serve as robust antiviral screening tools.
2. Materials and methods
2.1. Cells
Vero (African green monkey kidney), A549 (human lung epithelial carcinoma), HeLa 
(human cervical carcinoma), and HEK 293T (human embryonic kidney) cells were 
maintained at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented 
with 7.5% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 
mM L-glutamine. Baby hamster kidney cells stably expressing T7 polymerase (BSRT7/5) 
(Buchholz et al., 1999) were incubated at every third passage in the presence of 1 mg/mL 
G-418 (Geneticin).
2.2. Cloning and rescue of recombinant viruses
For LUC2AM, a modified NiV M gene fragment expressing the Renilla luciferase 
(Promega) open reading frame (ORF) in-frame with the NiV Matrix (M) gene ORF 
separated by the FMDV 2A protease cleavage peptide was constructed using a 4-step 
Lo et al. Page 2













overlapping PCR strategy as described for a DsRed-Express reporter NiV (RED2AM) and 
inserted into a plasmid containing a full-length cDNA copy of wild-type recombinant NiV 
genome using engineered SbfI and SacII restriction sites (Lo et al., 2012). The total genome 
length of LUC2AM was 19,254 nt.
The GFP2AM expressing the green fluorescence protein Zsgreen1 (Clontech) ORF in-frame 
with the NiV M gene ORF separated by the porcine teschovirus 2A (p2A) protease cleavage 
peptide was constructed using a second-generation wild-type recombinant NiV (rNiV) 
(Genbank sequence AF212302) devoid of engineered restriction sites, assembled via 4 
fragments into the same plasmid backbone used for LUC2AM (Genscript). A synthesized 
fragment containing the GFP, p2A, and NiV M coding sequence in-frame was cloned into 
WT using PacI restriction sites. An additional 3 nucleotides “GGA” encoding the amino 
acid glycine were inserted between the end of the Zsgreen1 ORF and the start of the p2A 
cleavage peptide for the final genome length to obey the “Rule of six” at 19,014 nt 
(Kolakofsky et al., 1998). Both LUC2AM and GFP2AM were rescued as previously 
described (Lo et al., 2012). The genomes of the rescued viruses were fully sequenced with 
no undesired mutations. Virus stock titers were determined by median tissue culture 
infectious dose (TCID50) assay (see below).
2.3. Infections with recombinant reporter viruses, reporter activity measurements, cell type 
optimization, TCID50
All infections in this study were performed in 96-well plates. Cells were seeded in opaque 
black or white plates (Costar 3916, 3917) for fluorescence and luminescence-based assays 
respectively. Initial time course experiments for rescued viruses were performed by infecting 
2 × 104 Vero cells/well at multiplicity of infection (MOI) = 0.01 TCID50/cell of either virus 
for 2 h. Virus inoculum was removed and replaced with 100 μL Fluorobrite medium (Life 
Technologies) supplemented with 2 mM L-glutamine and 10% FBS. At 24, 48, and 72 h 
post-infection (hpi), supernatants were harvested for TCID50 determination and replaced 
with Fluorobrite medium. Fluorescence activity (gain = 65) was measured in a H1 Synergy 
plate reader (Biotek), while luminescence activity (gain = 107) was measured in the same 
reader 10 min after addition of Renilla-Glo substrate (Promega). Subsequent infections were 
performed at MOI = 0.2 TCID50/cell unless stated otherwise. Cytopathic effect-based 
TCID50 assays were performed by infecting Vero cells in 10-fold dilution series of samples 
(10− 1–10−8) in a 96- well plate format, infecting 9 wells per sample and dilution step. Plates 
were read after 7 days to ensure a clear distinction between infected and uninfected wells at 
the highest dilutions.
2.4. Fluorescence microscopy
2 × 104 HeLa cells were infected with LUC2AM or GFP2AM, and at 24 hpi were fixed in 
10% formalin for 15 min, permeablized with PBS + 0.4% Triton-X for 5 min, washed with 
PBS + 0.1% Tween (PBS-T), and blocked with PBS-T + 5% milk (PBS-T-M) for 30 min. 
LUC2AM-infected cells were incubated with a mouse anti-NiV-N monoclonal antibody 
1A11C1 (Chiang et al., 2010) and a rabbit anti-Renilla luciferase antibody (MBL) diluted 
1:1000 and 1:200 respectively in PBS-T-M for 1 h at 37 °C, while GFP2AM-infected cells 
were incubated with only 1A11C1 antibody. After 3 washes with PBS-T, cells were 
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incubated with anti-mouse DyLight 550 and anti-rabbit DyLight 488 antibodies (Bethyl 
Laboratories, Inc.) diluted 1:1000 in PBS-T-M for 30 min at 37 °C. After 3 washes, 
fluorescence images were taken on a Zeiss Axiovert 200 microscope at 40X magnification.
2.5. Antiviral compounds, assessment of cell viability (CC50) and 50% effective 
concentrations (EC50)
The following compounds used in this study were dissolved in dimethyl sulfoxide (DMSO): 
6-azauridine acetate (Sigma), Pyrazofurin (TRC), and compound 09167 (Vitas-M 
Laboratory) (Yan et al., 2013). The final DMSO concentration in Fluorobrite media was 
0.1%. Universal interferon (U-IFN) (Sigma) was dissolved in sterile distilled H2O. The 
CellTiter-Glo assay (Promega) was used to determine viability of uninfected 293T cells 
exposed to 3-fold serial dilutions of the compounds for 48 h. Values were normalized to 
DMSO controls according to % viability as follows: % viability = [(specific value–reference 
value)/(DMSO control value − reference value)] × 100. Reference values were derived from 
control wells without cells. DMSO control values (after subtraction of reference values) 
were set at 100% viability. 50% viability/cytotoxicity (CC50) and 50% effective 
concentrations (EC50) were calculated using four-parameter variable slope non-linear 
regression fitting of mean values for three experiments. Therapeutic indices (TI) were 
represented as CC50/EC50. In instances which CC50 could not be properly calculated due to 
non-convergence of dose response curves, we designated the highest concentration of 
compound used as the CC50.
2.6. Statistical analysis
Statistical analysis was performed using Prism 6 software (GraphPad Software). Z′ 
(separation band/dynamic range of the assay) values were calculated based on the following 
formula: Z′ = 1 − [(3SDC + 3SDB)/(meanC − meanB)], where SD is the standard deviation, 
C is the control, and B is the background (Zhang et al., 1999). The percent coefficient of 
variation (%CV) was calculated as follows: %CV = SDC/meanC × 100.
3. Results and discussion
3.1. Construction and characterization of luciferase and GFP expressing NiVs
To evaluate the use of luminescent reporters for antiviral screening against NiV, we 
constructed a Renilla luciferase-expressing NiV (LUC2AM) by employing previous 
methods used to generate a red fluorescent protein-expressing NiV (RED2AM) (Lo et al., 
2012). We inserted the Renilla luciferase (LUC) gene into the NiV matrix (M) gene 5′ of 
the MORF in the same reading frame, separated by the coding sequence of the Foot and 
Mouth Disease virus protease cleavage peptide (F2A) (Fig. 1A). We used the same strategy 
to construct a second generation recombinant green fluorescent protein(GFP)-expressing 
NiV (GFP2AM), except that we used the more efficiently-cleaved porcine Teschovirus 2A 
cleavage peptide (p2A) coding sequence instead of F2A (Kim et al., 2011) (see Section 2). 
We rescued both LUC2AM and GFP2AM and confirmed expression of their respective 
reporter proteins by immunofluorescence microscopy. The distribution of both LUC and 
GFP were distinct from NiV nucleoprotein, with the luciferase localizing exclusively to the 
cytoplasm, and with the GFP occupying both nuclear and cytoplasmic compartments (Fig. 
Lo et al. Page 4













1B). While GFP2AM grew similarly in Vero cells (MOI = 0.01 TCID50/cell) compared with 
the non-reporter recombinant (rNiV) (Fig. 1C, right) LUC2AM had an attenuated growth 
phenotype when compared with its corresponding first generation non-reporter recombinant 
NiV (WT) (Fig. 1C, left). This is consistent with previous observations that the RED2AM 
virus was moderately attenuated compared with WT (Lo et al., 2012). Furthermore our 
result is consistent with previous work showing that NiV M requires ubiquitination inside 
the nucleus to become functional for budding (Wang et al., 2010), since the comparatively 
less-efficient cleavage of F2A would result in decreased amounts of functional NiV M for 
budding new virus particles. In spite of this phenotype however, LUC2AM generated 
increasing levels of LUC activity from 0 to 48 h postinfection (hpi), and reached viral titers 
of over 106 TCID50/mL by 72 hpi (Fig. 1C, left panel). The fluorescence signal generated by 
GFP2AM was detectable at 24 hpi, but increased by greater than 20-fold at 48 hpi, and 
continued to increase through 72 hpi. The accumulation of GFP signal over the course of 
infection corresponded with the increase in GFP2AM viral titer (Fig. 1C, right panel).
3.2. Optimization of cell type and infection conditions for LUC2AM and GFP2AM-based 
assays
We then optimized both assays for antiviral testing. We tested each virus against 3 common 
human cell lines (A549, HeLa, 293T) alongside Vero cells to determine which would yield 
the strongest reporter signal over the course of infection. For negative controls, we assayed 
for reporter activity in each cell line infected with wild-type recombinant NiV (rNiV). 
Infection with LUC2AM over the course of 72 h (MOI = 0.1 TCID50/cell) showed that HeLa 
and 293T cells supported peak LUC activity to approximately equal or greater levels than in 
Vero cells, while A549 only marginally supported LUC activity (Fig. 2A, left panel). In both 
Vero and HeLa cells, LUC signal peaked at 24 hpi (~4–5 × 104 relative light units) and 
steadily decreased by over 10-fold by 72 hpi. In 293T cells however, the LUC signal was 
approximately equal to those of Vero and HeLa cells at 24 hpi, but proceeded to double by 
48 hpi (~8 × 104 RLU) before decreasing at 72 hpi to levels similar to 24 hpi. Infection with 
GFP2AM yielded similar results, showing minimal NiV replication in A549 cells, and 
indicating 293T cells as the optimal cell type which generated the highest GFP signal 
onward from 48 hpi to 72 hpi (Fig. 2A right panel). In contrast to the LUC2AM infections 
however, all 4 infected cell lines attained their highest levels of GFP expression at 72 hpi. 
The different reporter signal kinetics observed when comparing LUC2AM and GFP2AM 
infections are likely a function of respective reporter protein maturation rates and half-lives. 
Whereas LUC matures rapidly and has a protein half-life of approximately 14 h in the cell 
cytoplasm (Loening et al., 2006), GFP requires 8–12 h for maturation, and has a protein 
half-life of approximately 26 h (Corish and Tyler-Smith, 1999). Since the peak LUC signal 
in infected 293T cells occurred at 48 hpi, and because of the minimal difference in GFP 
signal between 48 hpi and 72 hpi, we chose 48 hpi as our assay time point for both 
LUC2AM and GFP2AM.
To further optimize these reporter assays, we infected 293T cells with either reporter virus at 
MOIs ranging from 0.05 to 0.4 TCID50/cell. Increasing the MOI for both LUC2AM and 
GFP2AM led to corresponding increases in reporter activity (Fig. 2B). Since the increase in 
MOI from 0.2 to 0.4 for both LUC2AM and GFP2AM only marginally increased their 
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respective reporter activity (less than 2-fold), we used MOI = 0.2 TCID50/cell for both 
reporter viruses for our antiviral assays. We performed growth curves for both viruses in 
293T cells by infecting at MOI = 0.2 TCID50/cell, and observed increases in reporter signals 
corresponding with increases in virus titers (Fig. 2C).
3.3. Testing antiviral inhibitors against LUC2AM and GFP2AM
Having optimized both fluorescent and luminescent reporter assays in 293T cells, we 
assayed LUC2AM and GFP2AM against two known inhibitors of NiV, 6-azauridine acetate 
and pyrazofurin. Both of these compounds inhibit cellular pyrimidine biosynthesis via 
blocking orotidine 5′-monophosphate decarboxylase (Bono et al., 1964; Georges-Courbot et 
al., 2006; Gutowski et al., 1975). Consistent with a prior study utilizing a CPE-based assay 
(Georges-Courbot et al., 2006), 6-azauridine acetate and pyrazofurin showed dose-
dependent inhibition of LUC2AM and GFP2AM, reducing reporter activity to background 
levels at the highest doses (25–50 μM) while having mild to minimal effects on cell viability 
(Fig. 3A). The respective 50% effective concentrations (EC50) determined for each 
compound using the LUC2AM and GFP2AM were within 3-fold of each other (Table 1).
Since several studies have demonstrated the sensitivity of henipaviruses to type-1 interferon 
(IFN) signaling (Dhondt et al., 2013; Escaffre et al., 2013; Virtue et al., 2011), we evaluated 
the antiviral effect of universal interferon (U-IFN) against our reporter viruses. Although 
increasing concentrations of U-IFN led to corresponding decreases in respective reporter 
activity, even the highest concentration (1000 IU) of U-IFN only reduced LUC and GFP 
activity by approximately 4-fold and 3-fold respectively (Fig. 3B, top panels). These results 
are consistent with the early expression of multiple antagonists of IFN signaling by NiV 
(Kulkarni et al., 2009; Rodriguez et al., 2002; Shaw et al., 2005). EC50 values for U-IFN 
against LUC2AM and GFP2AM were nearly identical (Table 1). In addition to U-IFN we 
also tested compound 09167, a recently characterized agonist of the innate antiviral response 
(Yan et al., 2013) (Fig. 3B, lower panels). In contrast to U-IFN, treatment with compound 
09167 was able to completely ablate both LUC and GFP activity at the highest dose tested 
(12.5 μM), indicating that IFN signaling-independent components have crucial roles in 
blocking NiV replication. Dose response curves for compound 09167 against both 
LUC2AM and GFP2AM confirmed sub-micro molar EC50s, which were consistent with 
EC50s previously obtained for 09167 against other paramyxoviruses (Yan et al., 2013) (Table 
1). Further studies of this compound’s effect on cell viability are warranted to determine its 
suitability for antiviral testing in vivo.
3.4. Counter screening against wild-type NiV, evaluating reporter assays for high-
throughput screening
To confirm whether the dose–response curves and EC50 values obtained using these reporter 
viruses reflected actual inhibition of NiV replication, we tested 6-azauridine acetate and 
compound 09167 against wild-type non-recombinant NiV via virus yield-based dose–
response assays (Fig. 4A). We observed dose-dependent reductions in virus titers to below 
initial levels of input virus at the two highest doses for each compound (>4 Log10 
TCID50/mL reduction), suggesting complete ablation of viral replication at these 
concentrations. EC50 values calculated for 6-azauridine and 09167 against wild-type NiV 
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were within 1 Log10 of EC50 values derived for each compound against LUC2AM and 
GFP2AM, indicating that inhibition of the reporter viruses paralleled inhibition of NiV 
replication (Fig. 4B, Table 1). The moderately higher EC50s calculated from the reporter 
viruses suggest a lesser likelihood to detect false positives in the context of high-throughput 
screening (HTS). To quantitatively assess the suitability of these two viruses for HTS, we 
used compound 09167 as a positive control for inhibition and calculated Z′ factor values, 
signal-to-noise ratios, and coefficients of variation for the 96-well plate format used 
throughout this study. For both assays, these values were robust and well within the 
acceptable range for HTS (Zhang et al., 1999) (Table 2).
4. Conclusions
The primary advantages to using viral reporter assays over viral antigen-based assays are the 
significant reduction in assay turnaround time and the minimal reagents required. Whereas a 
previously described henipavirus immunodetection assay required at least 2 h of post-
infection processing (fixing, blocking, antibody staining) before the plate reading step, the 
LUC2AM assay required just 10 min of reagent incubation before plate reading, while the 
GFP2AM assay required even less time since no additional reagents were required. The 
LUC2AM assay has several advantages over the GFP2AM assay including better signal-to-
noise ratios and less variability between samples/wells. Although we established the 
LUC2AM assay to be read alongside the GFP2AM assay at 48 hpi, the robust signal-to-
noise ratio and Z′ values for LUC2AM at even 24 hpi would allow for adaptation of the 
assay to span a shorter infection period, whereas this would not be possible for GFP2AM 
due to its longer maturation time (data not shown). The GFP2AM assay has some 
advantages over LUC2AM assay in that GFP activity can be measured multiple times, 
whereas LUC measurement is an endpoint measurement. Furthermore, GFP2AM can be 
easily adapted for high content imaging to simultaneously assess cell viability and reporter 
activity, as well as for flow-cytometry-based applications. In sum, we established reporter 
NiVs that will not only facilitate antiviral screening, but also the study of cellular 
components that influence viral replication.
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Design and characterization of reporter Nipah (NiV) viruses. (A) Schematic of wild-type 
NiV genome alongside reporter NiVs expressing either luciferase (LUC2AM) or green-
fluorescent protein (GFP2AM) respective nucleotide (nt) lengths indicated. Black segments 
represent non-coding regions, while white segments indicate open reading frames. Modified 
M gene coding regions for LUC2AM and GFP2AM are highlighted in yellow and green 
respectively. (B) Microscopic examination of HeLa cells infected with LUC2AM and 
GFP2AM. LUC2AM-infected were stained with antibodies against NiV nucleoprotein (N) 
and anti-Renilla luciferase antibodies, while GFP2AM-infected cells were stained only with 
N antibodies. (C) Time course analysis of growth kinetics and reporter activities of 
LUC2AM and GFP2AM alongside the growth kinetics of their corresponding wild-type 
recombinant NiVs (WT, rNiV respectively). Vero cells were infected with each virus at an 
MOI of 0.01. At 1, 2, and 3 days post-infection, supernatants titers were determined by 
TCID50, (left Y-axis) while relative light units (RLU) or relative fluorescence units (RFU) in 
the cells infected with reporter viruses were measured (right Y-axis). Reporter activity levels 
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at day 0 post-infection indicate background noise of the luminometer/fluorometer. Values 
represent means and standard deviations for 3 experiments.
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Assay optimization. (A) 293T cells yielded the highest reporter activity levels for both 
LUC2AM and GFP2AM reporter viruses. (B) 293T cells were infected at the indicated 
multiplicity of infection (MOI) with LUC2AM or GFP2AM, and respective reporter values 
were measured at 48 hpi. (C) Time course analysis of growth kinetics and reporter activities 
of LUC2AM and GFP2AM in 293T cells (MOI = 0.2 TCID50/cell). At 1, 2, and 3 days post-
infection, supernatant titers were determined by TCID50 (left Y-axis), while respective 
reporter activities in the cells were measured (right Y-axis). Values represent means and 
standard deviations for 3 experiments.
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Reporter NiVs as tools for antiviral testing. (A) Testing of 2 known inhibitors (6-azauridine 
acetate and pyrazofurin) of pyrimidine biosynthesis and (B) 2 innate immune agonists 
(Universal interferon and compound 09167) against LUC2AM (left panels) and GFP2AM 
(right panels). 293T cells were infected with reporter NiVs (MOI = 0.2 TCID50/cell) for 2 h, 
and then incubated with indicated compounds in 3-fold serial dilutions. Each concentration 
was assessed in three replicates. Reporter virus activity was measured on the left Y-axis; % 
cell viability was measured on the right Y-axis. Values represent means and standard 
deviations of 3 experiments.
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Confirmatory counter-screening against wild-type NiV. (A) Virus titer-reduction assays. 
293T cells were infected with wild-type NiV (MOI = 0.2 TCID50/cell) for 2 h, and then 
incubated with 3-fold dilutions of 6-azauridine acetate (left panel) or compound 09167 (right 
panel) for 48 h. Supernatant virus titers were determined by TCID50 titrations and plotted 
against compound concentration. Values represent means and standard deviations of 3 
experiments. Virus titers were then (B) normalized to vehicle (DMSO) controls. EC50s were 
calculated based on four-parameter variable-slope nonlinear regression models. Normalized 
data points represent means for three experiments.
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Table 1
50% effective concentrations (EC50) of compounds against reporter and wild-type NiVs (therapeutic indices in 
parentheses).
Inhibitor ID Units NiV-LUC2AM NiV-GFP2AM NiV-MY-99
6-Azauridine acetate μM 0.274 ± 0.0357 (⩾364) 0.553 ± 0.151 (⩾180) 0.120 ± 0.0445 (⩾833)
Pyrazofurin μM 0.432 ± 0.0871 (⩾115) 0.281 ± 0.0448 (⩾177) ND
09167 μM 0.0723 ± 0.0123 (877) 0.254 ± 0.0905 (249) 0.0289 ± 0.0102 (2196)
U-IFN IU 10.96 ± 4.90 (⩾91) 10.2 ± 8.49 (⩾98) ND
ND - Not done.
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Table 2
Comparison of Nipah LUC2AM and GFP2AM assays used in this study.
Plate format Target virusa Z′valueb S/N ratioc %CV
96 wells NiV-LUC2AM 0.85 1.33E + 04 5%
96 wells NiV-GFP2AM 0.67 2.16E + 03 11%
a
293T cells were infected with either LUC2AM or GFP2AM viruses for 2 h before treatment with host antiviral agonist compound 09167 (final 
concentration, 12.5 mM) or an equivalent amount of vehicle (DMSO). Relative luciferase/fluorescence units were determined at 48 hpi.
b
Z′ factor (Zhang et al., 1999). Statistical analyses were based on means of four independent experiments.
c
Ratio of signal to background noise.
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